Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Diabetes Research and Clinical Practice

• Publication date

  2007-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.DIABRES.2006.11.014PMID 17240472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Telmisartan But Not Valsartan Increases Caloric Expenditure and Protects Against Weight Gain and Hepatic Steatosis

  2006cited by this paper
• Cardiovascular Diabetology BioMed Central Original investigation Metabolic effect of telmisartan and losartan in hypertensive

  2005cited by this paper
• Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.

  2005cited by this paper
• Possible beneficial effect of telmisartan on glycemic control in diabetic subjects.

  2005cited by this paper
• Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study.

  2004cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004cited by this paper
• Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity

  2004cited by this paper
• Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity

  2004cited by this paper
• Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease.

  2004cited by this paper
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

  2003cited by this paper
• Cognitive Function and Health-Related Quality of Life in Elderly Patients with Hypertension - Baseline Data from the Study on COgnition and Prognosis in the Elderly (SCOPE)

  2002cited by this paper
• Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.

  2002cited by this paper
• Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats

  2001cited by this paper
• Blood-pressure reduction and cardiovascular risk in HOPE study.

  2001cited by this paper
• Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.

  2000cited by this paper
• Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists

  2000cited by this paper
• Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

  1999cited by this paper
• Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives.

  1995cited by this paper
• A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.

  1989cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Telmisartan vs. other antihypertensives on cardiometabolic and vascular outcomes in diabetic hypertension: A randomised trial

  2026cites this paper
• Hypertension in metabolic syndrome

  2025cites this paper
• [Sartans in the treatment of arterial hypertension: focus on telmisartan and azilsartan. A review].

  2023cites this paper
• Comparative Study of the Effects of Azilsartan and Telmisartan on Insulin Resistance and Metabolic Biomarkers in Essential Hypertension Associated With Type 2 Diabetes Mellitus

  2022cites this paper
• PPAR Modulation Through Posttranslational Modification Control

  2021cites this paper
• Investigation of Antiinflammatory and Antioxidant Effects of Glycyrrhizin on Rats with Experimental Diabetes

  2019cites this paper
• Comparative Effects of Telmisartan versus Valsartan on serum Leptin level, in hypertensive type 2 diabetes mellitus patients

  2019cites this paper
• Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial

  2019cites this paper
• EURASIAN JOURNAL OF HEALTH SCIENCES

  2019cites this paper
• Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets

  2017cites this paper
• Positive correlation of serum leptin levels with obesity and metabolic syndrome in patients with type 2 diabetes mellitus

  2017cites this paper
• Telmisartan Ameliorates Nephropathy in Metabolic Syndrome by Reducing Leptin Release From Perirenal Adipose Tissue

  2016cites this paper
• Effect of irbesartan on blood glucose levels in a mice model of type 2 diabetes mellitus

  2016cites this paper
• Dietary Flavonoids Added to Pharmacological Antihypertensive Therapy are Effective in Improving Blood Pressure

  2015cites this paper
• Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis

  2015cites this paper
• Effect of Irbesartan on Glucose Tolerance in a Type 2 Diabetes Mellitus Mouse Model

  2015cites this paper
• A Comparative Study of Olmesartan and Valsartan on Insulin Sensitivity in Hypertensive Patients with Diabetes Mellitus or Impaired Glucose Tolerance (OVIS Study)

  2014cites this paper
• Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass

  2014cites this paper
• Antihypertensive drugs and glucose metabolism.

  2014cites this paper
• Reduced total and cause-specific mortality from walking and running in diabetes.

  2014cites this paper
• Walking and Running Produce Similar Reductions in Cause-Specific Disease Mortality in Hypertensives

  2013cites this paper
• A Review on: Telmisartan

  2013cites this paper
• Renin‐angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease

  2013cites this paper
• Changes in biomarkers and 24 hours blood pressure in hypertensive African Americans with the metabolic syndrome: comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan.

  2013cites this paper
• Telmisartan Improves Cardiometabolic Profile in Obese Patients with Arterial Hypertension

  2012cites this paper
• Metabolic effect of combined telmisartan and nifedipine CR therapy in patients with essential hypertension

  2012cites this paper
• Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation.

  2012cites this paper
• Double blockade of angiotensin II (AT1)‐receptors and ACE does not improve weight gain and glucose homeostasis better than single‐drug treatments in obese rats

  2012cites this paper
• The Effects of Antihypertensive Agents in Metabolic Syndrome – Benefits Beyond Blood Pressure Control

  2012cites this paper
• Pleiotropic effects of telmisartan beyond blood pressure control

  2011cites this paper
• Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus

  2011cites this paper
• Telmisartan Lowers Home Blood Pressure and Improves Insulin Resistance Without Correlation Between Their Changes

  2011cites this paper
• The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function

  2011influential citation
• Effects of Improving Glycemic Control with Insulin on Leptin, Adiponectin, Ghrelin and Neuropeptidey Levels in Patients with Type 2 Diabetes Mellitus: a Pilot Study

  2011cites this paper
• Hyperleptinaemia positively correlated with metabolic syndrome in hemodialysis patients.

  2011cites this paper
• Glucose metabolism and blood pressure remain unchanged by addition of angiotensin receptor blocker in patients undergoing hemodialysis

  2011cites this paper
• Selective modulation of PPARgamma activities in marrow mesenchymal stem cells and their effects on bone

  2011cites this paper
• Pharmacological and non-pharmacological interventions to influence adipose tissue function

  2011influential citation
• Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice.

  2011cites this paper
• Telmisartan Improves Insulin Resistance in Patients With Low Cytokine Levels

  2011cites this paper
• Effects of one-year swimming training on blood pressure and insulin sensitivity in mild hypertensive young patients.

  2010cites this paper
• Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose.

  2010cites this paper
• Normalization effect of sports training on blood pressure in hypertensives

  2010cites this paper
• The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone.

  2010cites this paper
• Open-label, Randomized Crossover Study Between Telmisartan and Valsartan on Improving Insulin Resistance and Adipocytokines in Nondiabetic Patients with Mild Hypertension

  2010cites this paper
• The role of the novel adipocyte-derived protein adiponectin in human disease: an update.

  2010cites this paper
• Hyperleptinemia positively correlated with metabolic syndrome in renal transplant recipients

  2010cites this paper
• Valsartan Increases Circulating Adiponectin Levels without Changing HOMA-IR in Patients with Type 2 Diabetes Mellitus and Hypertension

  2010cites this paper
• Fasting Serum Leptin Level Correlates With Mid‐Arm Fat Area in Peritoneal Dialysis Patients

  2010cites this paper
• Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance.

  2010cites this paper
• Telmisartan reduced abdominal circumference and body weight with decreasing triglyceride level in patients with type 2 diabetes and metabolic syndrome.

  2010cites this paper
• Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse

  2010cites this paper
• Are the pleiotropic effects of telmisartan clinically relevant?

  2009cites this paper
• Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity.

  2009cites this paper
• Beneficial Effects of Telmisartan in an HIV+ Diabetic Insulin-Dependent Patient

  2009cites this paper
• Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.

  2009cites this paper
• Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGF-beta1 levels in ovariectomized rats.

  2009cites this paper
• Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension.

  2009cites this paper
• Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.

  2009cites this paper
• Current literature in diabetes

  2008cites this paper
• Comparison of the Effects of Telmisartan and Olmesartan on Home Blood Pressure, Glucose, and Lipid Profiles in Patients with Hypertension, Chronic Heart Failure, and Metabolic Syndrome

  2008cites this paper
• THE RISK OF DEVELOPING DIABETES IN HYPERTENSION : -Insulin sensitivity, AT-1 receptor blockade and sympathetic activity

  2008cites this paper
• Interactions of glucose metabolism and chronic heart failure.

  2008cites this paper
• The renin–angiotensin–aldosterone system: a pivotal role in insulin sensitivity and glycemic control

  2008cites this paper
• Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes.

  2008cites this paper
• Bibliography. Current world literature. Diabetes and the endocrine pancreas.

  2008cites this paper
• Angiotensin II Blockade and Total Cardiovascular Risk

  2008cites this paper
• Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension

  2008cites this paper
• Telmisartan Treatment Decreases Visceral Fat Accumulation and Improves Serum Levels of Adiponectin and Vascular Inflammation Markers in Japanese Hypertensive Patients

  2007cites this paper
• Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect?

  2007cites this paper
• Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?

  2007cites this paper
• Diabetes and the endocrine pancreas Acute myocardial infarction in diabetes

  year unknowncites this paper
• Сартаны в лечении артериальной гипертензии: фокус на телмисартан и азилсартан

  year unknowncites this paper